


At a Glance

Profile HBM Healthcare Investments actively invests in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. The company holds and manages an international portfolio of some twenty-five promising companies. Many of these companies have their lead products already available on the market or at an advanced stage of

development. The portfolio companies are closely tracked and actively guided in their strategic directions. This is what makes HBM Healthcare Investments an interesting alternative to investing in big pharma and biotech companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).




Allocation of assets

Mainly invested in private companies or companies originating from the private portfolio.




Currency allocation

Emphasis on US dollar investments.



Development phase of portfolio companies¹⁾

Largely invested in profitable companies or in companies with products available on the market.



Therapeutic area of the lead product of portfolio companies¹⁾

Broadly diversified areas of activity.

1) Total investments as at 31.12.2013: CHF 723 million.

Key Figures, Performance and the Ten Largest Direct Investments

		31.12.2013	31.3.2013	restated 31.3.2012	restated 31.3.2011	restated 31.3.2010
Key Figures						
Net assets	CHF million	816.2	601.0	546.4	593.2	666.1
Investments in private companies		188.9	233.4	276.3	370.8	533.1
Investments in public companies		534.4	278.9	196.7	83.4	100.3
Cash and cash equivalents		67.2	51.7	41.2	155.4	128.9
Net cash flow from investing activities	CHF million	54.6	33.2	-39.9	146.3	186.1
Net result for the period/for the year	CHF million	242.9	67.0	-22.2	-53.1	66.8
Basic earnings per share	CHF	28.05	7.52	-2.35	-5.39	6.46
Net asset value (NAV) per share	CHF	95.50	68.35	60.40	61.56	65.94
Share price	CHF	66.25	51.35	41.50	44.60	49.50
Discount		-30.6%	-24.9%	-31.3%	-27.6%	-24.8%
Par value repayment per share	CHF	1.50				
Distribution yield		2.9%				
Shares issued	Registered shares (m)	8.9	9.2	9.8	10.2	10.7
Shares outstanding	Registered shares (m)	8.5	8.8	9.0	9.6	10.1

		2013/2014	2012/2013	2011/2012	2010/2011	2009/2010
Performance						
HBM Healthcare Investments Ltd						
Net asset value (NAV)		39.7%	13.2%	-1.9%	-6.6%	12%
Registered share HBMN		29.0%	23.7%	-7.0%	-9.9%	125%
Relevant market index in Swiss francs						
MSCI World Health Care Index		10.6%	28.7%	8.1%	-9.9%	22.0%

		Fair value (CHF 000)	As % of net assets
The Ten Largest Direct Investments as at 31.12.2013			
Private companies			
Cathay Industrial Biotech		25,001	3.1
Interventional Spine		15,140	1.9
Public companies			
Basilea Pharmaceutica ^{P)}		119,694	14.7
Ophthotech ^{P)}		105,149	12.9
Pacira Pharmaceuticals ^{P)}		86,865	10.6
SkyePharma ¹⁾		42,501	5.2
PTC Therapeutics ^{P)}		36,995	4.5
Allergan		24,746	3.0
Swedish Orphan Biovitrum ^{P)}		23,376	2.9
Enanta Pharmaceuticals ^{P)}		21,803	2.7

P) The position originates from the private companies portfolio.

1) The position includes shares and bond.

Dear Shareholders

During the quarter just ended, your Company's consolidated profit rose by CHF 70 million, to reach a total of CHF 243 million as of the first nine months of the current financial year. Net asset value (NAV) per share also increased over the past three months, by 10 percent to CHF 95.50, whilst the share price advanced by 2 percent to close at CHF 66.25.

The market valuation of our largest holding, Basilea Pharmaceutica, soared by a further 35 percent during the quarter under review, fuelled by positive data from the phase-III study of the company's Isavuconazole antifungal compound, and European market approval for its Ceftobiprole antibiotic. The Basilea holding contributed CHF 44.4 million to the results.

The investment in Pacira Pharmaceuticals also continued to perform well. Revenues from the long-acting analgesic Exparel™ came to USD 30.5 million in the fourth quarter, taking the total for calendar 2013 to USD 76.2 million – compared with USD 14.6 million in 2012. Pacira's market capitalisation rose by 20 percent to just under USD 2 billion during the reporting period, and contributed around CHF 13.2 million to profits for the quarter.

SkyePharma has made significant progress in recent months. Commercial sales of the Flutiform® asthma preparation got off to a good start in Europe, and the drug was also approved in Japan. Furthermore, a number of GSK inhalation products (Breo™, Anoro™ and Relvar™) in combination with Ellipta™, which are based on SkyePharma technologies, received the approval for US and EU markets. These developments had a positive effect on the share price and on the valuation of SkyePharma's corporate bond, which contributed CHF 9.4 million in total to HBM Healthcare Investments' profit for the quarter. Moreover, the bond continues to present attractive value potential, with an annual yield to maturity of 23 percent over the next four years.

The pleasing quarterly results round off an excellent calendar 2013 for HBM Healthcare Investments. Factoring in the par value repayment of CHF 1.50 per share, net asset value has risen by 65 percent, while the share price advanced by 46 percent. This performance is in line with an overall very good trading year for equity investments, as illustrated by a comparison of various relevant share indices (total return, in CHF): MSCI World Health Care Index +33 percent, Swiss Market Index (SMI) +24 percent, Swiss Performance Index (SPI) +28 percent, Dow Jones Industrial Average Index +25 percent, Euro Stoxx 50 Index +24 percent.

**«In calendar year 2013
HBM's net asset value
has risen by 65 percent,
whilst the share price
advanced by 46 percent.»**

Investment activity

In the private companies segment of the portfolio, HBM Healthcare Investments invested a total of CHF 3.8 million in follow-on financing for existing portfolio companies. The ownership interest in Westmed was raised to over 20 percent with an additional investment of USD 1.5 million. Furthermore, smaller investments were made in Delenex (CHF 1.3 million), Tensys (USD 0.7 million) and Nabriva (EUR 0.3 million).

HBM Healthcare Investments has also conducted extensive evaluations of a number of potential new investments in recent months. We are confident that we will be able to report on the successful conclusion of one or more transactions before too long.

The investment fund portfolio netted the Company CHF 6.3 million in cash inflows during the reporting period.

From the portfolio of public companies, we took further profits from Basilea Pharmaceutica, and reduced our holding in the company to just under 12 percent. Meanwhile, we extended our holdings in Swedish Orphan Biovitrum and SkyePharma to some degree. HBM Healthcare Investments also invested some of its disposable funds in other, attractively valued companies which offer considerable value creation potential.

Outlook

The new year got off to a pleasing start for HBM Healthcare Investments. We are expecting more positive results from a number of our portfolio companies. In view of the significant share of the portfolio that is held in public companies, HBM Healthcare Investments is increasingly exposed to movements on the equity markets as a whole.

We will maintain our shareholder-friendly distribution programme over the next twelve months, and will make every effort to ensure that 2014 is another successful year for you, our valued shareholders.



Dr Andreas Wicki
CEO



Erwin Troxler
CFO

Consolidated Interim Financial Statements

Consolidated balance sheet

	Notes	31.12.2013	31.3.2013
Assets (CHF 000)			
Current assets			
Cash and cash equivalents		67,221	51,691
Receivables		269	2,004
Financial instruments		394	1,347
Total current assets		67,884	55,042
Non-current assets			
Investments	(2)	723,234	512,287
Other financial assets	(3)	27,135	34,655
Total non-current assets		750,369	546,942
Total assets		818,253	601,984
Liabilities (CHF 000)			
Short-term liabilities			
Financial instruments		733	236
Other short-term liabilities		1,252	787
Total short-term liabilities		1,985	1,023
Shareholders' equity			
Share capital	(4)	520,650	552,000
Treasury shares	(4)	-20,593	-19,867
Capital reserve		389,966	385,527
Accumulated income/loss		-73,755	-316,699
Total shareholders' equity		816,268	600,961
Total liabilities and shareholders' equity		818,253	601,984
Number of outstanding shares (in 000)		8,547	8,793
Net asset value (NAV) per share (CHF)		95.50	68.35

Consolidated Interim Financial Statements

Consolidated statement of income for the period 1 April to 31 December

	Notes	Quarter ended 31.12.2013	restated Quarter ended 31.12.2012	9-month period ended 31.12.2013	restated 9-month period ended 31.12.2012
Result from investment activities (CHF 000)					
Gains on investments	(2)	90,309	11,169	274,976	45,338
Losses on investments	(2)	-17,071	-43,190	-35,065	-52,737
Dividend income		0	0	11,970	0
Result from currency hedging transactions		0	0	236	0
Gains from other financial instruments		0	282	551	726
Losses from other financial instruments		-550	0	0	0
Gains on other financial assets		952	326	1,845	4,312
Losses on other financial assets		0	-319	-1,771	-5,189
Result from investment activities		73,640	-31,732	252,742	-7,550
Management fee	(6)	-2,714	-2,021	-7,286	-5,995
Personnel expenses		-553	-416	-1,474	-1,356
Other operating expenses		-315	-505	-1,062	-1,321
Result before interest and taxes		70,058	-34,674	242,920	-16,222
Financial income		7	4	24	169
Net result for the period		70,065	-34,670	242,944	-16,053
Number of outstanding shares, time-weighted (in 000)		8,581	8,872	8,662	8,944
Basic earnings per share (CHF)		8.16	-3.91	28.05	-1.79

As the Company does not have options or similar instruments outstanding, diluted earnings per share are identical to basic earnings per share.

Consolidated statement of comprehensive income for the period 1 April to 31 December

(CHF 000)	Quarter ended 31.12.2013	restated Quarter ended 31.12.2012	9-month period ended 31.12.2013	restated 9-month period ended 31.12.2012
Net result for the period	70,065	-34,670	242,944	-16,053
Contribution to result reported in shareholders' equity				
Change owing to currency translation differences	0	0	0	0
Total comprehensive result	70,065	-34,670	242,944	-16,053

Consolidated Interim Financial Statements

Consolidated statement of cash flows

for the period 1 April to 31 December

(CHF 000)	<i>9-month period ended 31.12.2013</i>	<i>restated 9-month period ended 31.12.2012</i>
Management fee paid	-7,286	-5,995
Other expenses paid (personnel and other operating expenses)	-2,257	-2,962
Net cash flow from operating activities	-9,543	-8,957
Interest payments received	24	175
Dividend payments received	11,970	0
Purchase of investments	-160,247	-30,311
Sale of investments	192,055	30,473
Payments received from escrow amounts and milestones	8,584	1,816
Sale of other financial instruments	2,236	365
Net cash flow from investing activities	54,622	2,518
Par value repayment	-12,948	0
Purchase of treasury shares	-19,614	-18,277
Sale of treasury shares	4,925	8,275
Net cash flow from financing activities	-27,637	-10,002
Currency translation differences	-1,912	99
Net change in cash and cash equivalents	15,530	-16,342
Cash and cash equivalents at beginning of period	51,691	41,224
Cash and cash equivalents at end of period	67,221	24,882

Consolidated Interim Financial Statements

Consolidated statement of changes in equity

(CHF 000)	Share capital	Treasury shares	Capital reserve	Currency translation differences	Accumulated income/loss	Total shareholders' equity
Balance as at 31 March 2012 (restated)	588,000	-33,084	375,240	-57	-383,704	546,395
Net result for the period					-16,053	-16,053
Currency translation differences				57		57
Total comprehensive result						-15,996
Purchase of treasury shares		-18,277				-18,277
Sale of treasury shares		8,260	15			8,275
Capital reduction (4.9.2012)	-36,000	25,767	10,233			0
Balance as at 31 December 2012 (restated)	552,000	-17,334	385,488	0	-399,757	520,397
Net result for the period					83,058	83,058
Currency translation differences						0
Total comprehensive result						83,058
Purchase of treasury shares		-5,636				-5,636
Sale of treasury shares		3,103	39			3,142
Balance as at 31 March 2013	552,000	-19,867	385,527	0	-316,699	600,961
Net result for the period					242,944	242,944
Currency translation differences						0
Total comprehensive result						242,944
Purchase of treasury shares		-19,614				-19,614
Sale of treasury shares		4,170	755			4,925
Capital reduction (30.8.2013)	-18,000	14,718	3,282			0
Par value repayment (9.9.2013)	-13,350		402			-12,948
Balance as at 31 December 2013	520,650	-20,593	389,966	0	-73,755	816,268

Consolidated Interim Financial Statements

Notes

1. Summary of significant accounting policies

The consolidated interim financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS) IAS 34 on Interim Financial Reporting, and the provisions of the SIX Swiss Exchange Additional Rules on the Listing of Investment Companies. These interim financial statements should be read in conjunction with the Consolidated Financial Statements for the financial year ended 31 March 2013, as they provide an update to the latest full financial report. In preparing the interim financial statements, the same accounting policies and methods of computation have been applied as in the preparation of the annual financial statements.

A summary of the new and revised IFRS/IAS standards and interpretations effective in the year under review is provided on page 48 of the Consolidated Financial Statements of the 2012/2013 Annual Report. The use of these standards and interpretations had no significant impact on the financial condition or the earnings situation of the Company, or on its accounting policies.

The following exchange rates were used in the preparation of the financial statements:

(CHF)	31.12.2013	31.3.2013
DKK	0.1645	0.1632
EUR	1.2271	1.2168
GBP	1.4784	1.4426
SEK	0.1387	0.1454
USD	0.8929	0.9492

2. Investments

Investments developed as follows during the reporting period:

(CHF 000)	Private companies	Funds	Public companies	Total investments
Fair value as at 31 March 2013	152,599	80,792	278,896	512,287
Reclassification owing to IPO (PTC Therapeutics)	-20,976		20,976	0
Reclassification owing to IPO (Ophthotech)	-15,622		15,622	0
Adjusted fair value as at 31 March 2013	116,001	80,792	315,494	512,287
Purchases	6,494	4,390	149,363	160,247
Sales	-1,581	-9,184	-178,446	-189,211
Realised gains	0	68	26,562	26,630
Realised losses	-26,963	-662	-6,914	-34,539
Changes in unrealised gains	31,622	5,888	239,368	276,878
Changes in unrealised losses	-14,631	-3,374	-11,053	-29,058
Fair value as at 31 December 2013	110,942	77,918	534,374	723,234

Further details on investments can be found on pages 11 and 12.

3. Other financial assets

The sale of a number of investment positions has given HBM Healthcare Investments contractual claims to further purchase price payments that are contingent on the achievement of defined targets.

These claims are carried in the annual financial statements at a risk-weighted value, discounted over time (discount rate of 11 percent). The following summary shows the value carried in the balance sheet compared with the potential cash flows:

(CHF million)	Book value as at 31/12/2013	Range of possible cash flows, minimum	Range of possible cash flows, maximum	Expected period of payment
ESBATech	7.2	0.0	48.9	2014 – 2018
Mpex ¹⁾	2.5	1.7	>34.0	2014 – 2029
mtm laboratories	15.4	0.9	27.0	2015 – 2016
Other companies	7.0	1.6	22.0	2014 – 2019
Total	32.1	4.2	>131.9	

1) There is no ceiling on potential cash flows. The amount shown here is calculated on the basis of a sales estimate.

Of the total book value as at 31 December 2013, CHF 27.1 million is carried under other financial assets (claims from investments held by HBM Healthcare Investments directly). A further CHF 5.0 million is reported under investments, other private companies (claims from investments held indirectly via HBM BioCapital (EUR) L.P.).

If the companies concerned are successful, these contractual claims could result in future payments which are many times the reported book value.

ESBATech

The company was acquired in September 2009 by Alcon Inc. The purchase price comprised an advance payment of USD 150 million, as well as a further USD 439 million in milestone payments that are tied to the achievement of clinical development targets. In addition to the advance, HBM Healthcare Investments has to date received a small initial milestone payment. Further milestone payments are anticipated from 2014 onwards.

Mpex

The company was acquired in April 2011 by Axcen Pharma Inc. (now named Aptalis). Aptalis is paying the purchase price in cash – a guaranteed portion in tranches up to 2014, and the remainder as milestone payments contingent on market licensing and sales successes. HBM Healthcare Investments will receive another USD 2 million of guaranteed payments within 2014. Further payments of up

to USD 7 million will fall due upon the approval of the Aeroquin™ antibiotic in Europe and in the USA. HBM Healthcare Investments is also entitled to turnover-based payments on the basis of product sales up to 2029. These may correspond to several times the current book value of the investment.

mtm laboratories

The company was acquired in July 2011 by Roche. The purchase price of EUR 190 million comprised an advance payment of EUR 130 million and EUR 60 million as performance-based milestone payments. HBM Healthcare Investments has received the advance payment. The performance-related milestone payment is expected in 2015.

Other companies

“Other companies” relates primarily to contractual claims from the sale of the investment holdings in Adnexus, Asthmatx, Broncus, Nereus, Syntonix and Vivacta, which are tied to sales growth, advances in clinical development and product approvals.

4. Shareholders' equity

4.1 Share capital

As at the balance sheet date, the Company's share capital amounts to CHF 520.65 million, divided into 8,900,000 registered shares at a par value of CHF 58.50 each. The Ordinary Shareholders' Meeting of 21 June 2013 decided to cancel 300,000 treasury shares at the time held by the Company. In addition to this capital reduction, the Shareholders' Meeting approved a par value repayment to shareholders of CHF 1.50 per registered share, which was paid on 9 September 2013. Both capital reductions were entered in the Commercial Register of the Canton of Zug on 30 August 2013.

4.2 Treasury shares

The Ordinary Shareholders' Meeting of 22 June 2012 authorised the Board of Directors to repurchase a maximum of 920,000 of the company's own shares via a second trading line. The share buy-back programme is intended to reduce capital and will run until 30 June 2015 ("Share buy-back programme 2012"). Under this share buy-back programme a total of 400,400 of the Company's own shares have been repurchased to date. Thereof 190,000 of the Company's own shares, in combination with the not yet cancelled 110,000 shares acquired under the share buy-back programme 2009, were cancelled. The Company holds 210,400 of its own shares (31 March 2013: 263,000 own shares) as at the balance sheet date of 31 December 2013. In the 9-month period of the current financial year, a total of 247,400 of own shares were acquired over the second trading line at an average price of CHF 60.85.

In addition, as at the balance sheet date, HBM Healthcare Investments (Cayman) Ltd holds 142,584 treasury shares (144,362 as at 31 March 2013),

acquired over the regular trading line. During the 9-month period up to the end of December 2013, a total of 80,427 treasury shares were acquired over the regular trading line at an average price of CHF 56.70 per share (previous year: 197,144 shares at CHF 49.74), while 82,205 treasury shares were sold at an average price of CHF 59.92 (previous year: 171,278 shares at CHF 48.32). The gain of CHF 0.8 million (previous year: gain of CHF 0.015 million) from trading in treasury shares, which is reported in shareholders' equity, is based on the proceeds of shares sold, minus the pro-rata average acquisition price of all shares purchased over the regular trading line.

5. Investment commitments

(CHF 000)	31.12.2013	31.3.2013
HBM BioCapital (EUR) L.P.	1,008	2,046
HBM BioCapital II L.P.	41,265	44,008
Private companies	8,778	0
Funds	6,605	8,038
Total investment commitments	57,656	54,092

6. Management fees

The annual management fee to HBM Partners amounts to 1.2 percent of the Company assets plus 0.3 percent of the Company's market capitalisation. In the 9-month period up to the end of December 2013, HBM Partners was paid CHF 7.3 million (previous year: CHF 6.0 million).

7. Transactions with related parties

HBM Healthcare Investments holds an investment in the Hatteras Venture Partners III fund, where Robert A. Ingram, Member of the Board of Directors, serves as General Partner. For details on the investment commitment, paid-in capital and valuation, please refer to the overview of funds on page 12.

Investments

	Domicile	Investment currency (IC)	Amount disbursed as at 31.3.2013 (IC m)	Changes in the reporting period (IC m)	Amount disbursed as at 31.12.2013 (IC m)	Fair value as at 31.12.2013 (IC m)	Ownership as % of portfolio company	Fair value as at 31.12.2013 (CHF 000)	Fair value as at 31.3.2013 (CHF 000)
Private companies									
Cathay Industrial Biotech	China	USD	28.0		28.0	28.0	12.6	25,001	26,578
Interventional Spine	USA	USD	18.0		18.0	17.0	31.4	15,140	16,095
Tensys Medical ¹⁾	USA	USD	10.0	2.2	12.2	12.2	100.0	10,849	9,445
Nabriva Therapeutics ²⁾	Austria	EUR	13.1	0.3	13.4	7.6	11.9	9,360	15,890
Medimpulse Holding	Switzerland	USD	4.4		4.4	8.3	20.7	7,406	7,873
Ellipse Technologies ³⁾	USA	USD	8.0		8.0	8.0	24.7	7,146	7,597
Probiodrug	Germany	EUR	15.0	0.4	15.4	5.0	9.9	6,075	5,537
Delenix Therapeutics ²⁾	Switzerland	CHF	7.2	1.3	8.4	6.0	14.4	6,041	4,771
Westmed Holding	USA	USD	5.5	1.5	7.0	6.5	21.7	5,794	3,275
MiCardia ²⁾	USA	USD	4.3	0.3	4.6	3.7	11.5	3,282	4,068
Other investments								14,848	14,872
Total private companies								110,942	116,001

1) A lender of Tensys Medical Inc. has a convertible right into 30% of the total outstanding shares of Tensys Medical Inc. after conversion.

2) As explained in note 3 of the annual financial statements, this investment was made partly or wholly through HBM BioCapital (EUR) L.P. whose pro rata fees are reimbursed in full to HBM Healthcare Investments so that fees are not levied twice.

3) HBM Healthcare Investments holds an additional approx. 6.1% stake in the company indirectly via the MedFocus Fund since August 2005.

Funds	Domicile	Investment currency (IC)	Total commitment (IC m)	Payments in the reporting period (IC m)	Repayments in the reporting period (IC m)	Cumulative payments as at 31.12.2013 (IC m)	Cumulative repayments as at 31.12.2013 (IC m)	Fair value as at 31.12.2013 (IC m)	Fair value as at 31.12.2013 (CHF 000)	Fair value as at 31.3.2013 (CHF 000)
BioMedInvest I	Switzerland	CHF	26.0		6.2	26.0	14.0	15.7	15,652	16,900
MedFocus Fund II	USA	USD	16.0			16.0	0.0	13.3	11,873	13,014
Galen Partners V	USA	USD	10.0	0.7		9.4	0.0	10.9	9,740	9,688
HBM BioCapital II L.P. ¹⁾	Jersey	EUR	42.0	2.5		8.4	0.0	6.5	7,990	5,755
Hatteras Venture Partners III	USA	USD	10.0	0.5		8.0	2.0	8.0	7,149	7,104
Water Street Healthcare Partners	USA	USD	15.0	0.0	1.8	14.8	14.3	7.4	6,619	8,362
BioMedInvest II	Switzerland	CHF	10.0			6.0	0.0	5.4	5,390	5,130
Nordic Biotech	Denmark	DKK	31.0	1.2	0.9	31.0	11.8	27.1	4,463	4,264
BioVeda China	China	USD	8.5			8.5	27.2	4.4	3,965	4,093
Symphony Capital Partners	USA	USD	15.0		1.1	14.9	11.3	2.0	1,747	3,117
EMBL Technology Fund	Germany	EUR	2.1			2.1	0.0	1.2	1,412	1,413
BioVentures Investors II	USA	USD	3.0			3.0	0.5	1.3	1,130	844
Heidelberg Innovation BSV II	Germany	EUR	5.0		0.1	5.0	1.4	0.4	466	584
A.M. Pappas LifeScience Ventures II	USA	USD	3.0			3.0	3.3	0.2	198	323
Skyline Venture Partners III	USA	USD	3.0		0.1	2.9	3.8	0.1	124	200
Total funds									77,918	80,792

Public companies	Domicile	Investment currency (IC)	Number of shares as at 31.3.2013	Changes in number of shares over the last 9 months	Changes in number of shares over the last 3 months	Number of shares as at 31.12.2013	Ownership as % of portfolio company	Fair value as at 31.12.2013 (CHF 000)	Fair value as at 31.3.2013 (CHF 000)	
Basilea Pharmaceutica	P)	Switzerland	CHF	2,394,016	-1,258,404	-675,838	1,135,612	11.8	119,694	137,656
Ophthotech	P)	USA	USD	3,178,656	461,574	0	3,640,230	11.6	105,149	15,622
Pacira Pharmaceuticals	P)	USA	USD	2,233,993	-541,799	0	1,692,194	5.1	86,865	61,198
PTC Therapeutics	P)	USA	USD	1,841,495	600,000	-66,667	2,441,495	9.8	36,995	20,976
Allergan		USA	USD	1,500	248,000	149,500	249,500	0.1	24,746	159
SkyePharma Bond ²⁾		UK	GBP						23,410	0
SkyePharma		UK	GBP	4,976,806	6,476,339	526,339	11,453,145	24.8	19,091	3,338
Swedish Orphan Biovitrum	P)	Sweden	SEK	1,400,000	1,125,000	938,965	2,525,000	0.9	23,376	8,529
Enanta Pharmaceuticals	P)	USA	USD	1,441,989	-546,889	-172,401	895,100	5.0	21,803	24,911
Abbvie		USA	USD	3,000	253,000	250,000	256,000	0.0	12,071	116
Actavis		USA	USD	0	60,000	60,000	60,000	0.0	9,000	0
Wuxi Pharmatech		China	USD	0	207,500	104,650	207,500	0.3	7,111	0
Genmab		Denmark	DKK	10,000	180,000	-20,000	190,000	0.4	6,626	220
Morphosys		Germany	EUR	2,500	72,965	46,465	75,465	0.3	5,172	97
Oxford Immunotec		UK	USD	0	287,052	287,052	287,052	1.7	4,967	0
Intercept Pharmaceuticals		USA	USD	0	50,000	47,000	50,000	0.3	3,048	0
ChemoCentryx	P)	USA	USD	1,930,000	-1,930,000	-840,000	0		0	25,318
Other investments									25,250	17,354
Total public companies									534,374	315,494
Total investments									723,234	512,287

1) The fair value of EUR 6.5 million takes into account the funds' cumulative management fees of EUR 1.6 million. As described in note 3 to the annual financial statements, this amount was reimbursed in full to HBM Healthcare Investments so that fees are not levied twice.

2) Nominal GBP 16.932 million bond at 6.5% coupon plus 3% interest per year. The bond is valued at 93.52% of the nominal value. At maturity, it will be redeemed at 147.3%.

P) The position originates from the private companies portfolio.

Net asset value (NAV) and share price of HBM Healthcare Investments Ltd versus MSCI World Health Care Index

in CHF; indexed (12.7.2001 = 100)



Significant shareholders

Based on the notifications received by the Company, the following shareholders report equity holdings in HBM Healthcare Investments Ltd of three percent or more as at 31 December 2013:

Shareholding	Shareholder	Latest notification
10–15%	Alpine Select Ltd, Zug	2.10.2013
	Astellas Pharma Inc., Tokyo	7.4.2011
3–5%	Red Rocks Capital LLC, Golden	9.8.2013
	HBM Healthcare Investments Ltd, Zug (treasury shares)	4.9.2013

Information on shares

Swiss security number	1.262.725
German security number	984345
ISIN	CH 0012627250
CUSIP	H 3553X112
Telekurs	126,126272
SIX Swiss Exchange Ticker	HBMN
Internet	www.hbmhealthcare.com

Board of Directors

Hans Peter Hasler, Chairman
 Prof. Dr Dr h.c. mult. Heinz Riesenhuber¹⁾, Vice Chairman
 Mario G. Giuliani
 Dr Eduard E. Holdener
 Robert A. Ingram²⁾
 Dr Rudolf Lanz¹²⁾
 Dr Benedikt Suter, Secretary of the Board of Directors

1) Member of the Audit Committee
 2) Member of the Nominating Committee

Management

Dr Andreas Wicki, Chief Executive Officer
 Erwin Troxler, Chief Financial Officer

Fees

Management fees (paid quarterly):
 1.2% of Company assets plus
 0.3% of the Company's market capitalisation
 Performance fee (paid annually):
 15% on increase in value above the high water mark
 High water mark (per share for all outstanding shares):
 NAV of CHF 106.21

